Galapagos N.V. is a fully-integrated biopharmaceutical firm dedicated to discovering, developing, and bringing to market innovative therapies for conditions where patient needs are largely unaddressed. The company boasts a robust pipeline of investigational drugs, prominently featuring: Filgotinib: A potent JAK1 inhibitor, currently undergoing multiple phases of clinical evaluation for a broad spectrum of inflammatory and autoimmune disorders, such as rheumatoid arthritis, Crohn's disease (including small bowel and fistulizing forms), ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. GLPG1972: This key candidate has successfully completed its Phase 2b trial targeting osteoarthritis. Toledo Molecules: A series of these molecules (GLPG3970, GLPG4399, and GLPG4876) are under development with a focus on inflammatory conditions. GLPG4716 and Ziritaxestat: These compounds are being advanced to combat idiopathic pulmonary fibrosis. GLPG2737: Further diversifying the portfolio, this cystic fibrosis transmembrane conductance regulator (CFTR) modulator is currently in Phase 2 clinical trials for patients suffering from autosomal dominant polycystic kidney disease. GLPG0555: Moreover, this other JAK1 inhibitor is progressing through Phase 1b development for the management of osteoarthritis. Galapagos N.V. also maintains strategic collaboration agreements with prominent pharmaceutical partners, including Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG. Established in 1999, the company operates from its headquarters in Mechelen, Belgium.